ALG14

Across TCGA pan-cancer cohorts, ALG14 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ALG14 data layer compared with 27 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher ALG14 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated ALG14 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LSCC show a favorable association.

CCRCC, LSCC, and PDAC are the cancer types where ALG14 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	All	1.000	0.890	.005	24	view →
LSCC	OS	Median	All	0.912	0.682	<.001	16	view →
PDAC	OS	Median	III,IV	0.773	0.209	.010	6	view →
HNSC	DFS	Median	III,IV	0.922	1.000	.034	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ALG14–CCRCC (OS)

Open the CCRCC breakdown →